Waiting for ODAC
This article was originally published in RPM Report
Executive Summary
Investors in Amgen Inc. and Johnson & Johnson are staying on the sidelines until after a March 13 FDA advisory committee takes yet another look at the safety profile of the EPO brands Aranesp and Procrit. Here is a sampling of what analysts (and the two sponsors) are saying about the upcoming meeting.